Today, CHI FENG was honored to welcome the Alibaba.com team for a meaningful and in-depth discussion. The esteemed attendees included:

• Yu Fei, General Manager, Asia-Pacific Region
• Li Huabin, Operations Director, Asia-Pacific Region
• Chen Baogui, General Manager, Taiwan Region
• Yan Shuyao, Regional Manager, Northern Taiwan

Key Discussion Highlights:

1. The Alibaba.com team explored CHI FENG’s business model in the medical industry through cross-border e-commerce.
2. We shared insights into the IV consumables industry across different countries, including:
   • Certification requirements
   • Logistics and transportation methods
   • Transaction details (e.g., royalties for advanced medical product patents)
   • Customer acquisition strategies
3. We introduced the evolution of medical product usage, emphasizing:
   • The transition from traditional IV products to safety-focused needle-free products
   • How needle-free IV solutions reduce the risks of needle-stick injuries and enhance safety
   • The benefits of CSTD products for chemotherapy, which prevent contamination from needles, ensure clean drug extraction, and protect against drug leakage
   • How QuikLock accessories improve efficiency and safety for pharmacists, enabling faster and more effective operations

Alibaba.com Suggestions:

• Yu Fei, General Manager, highlighted the potential of leveraging Alibaba.com’s new tool, OKKI, to identify new customer sources and expand sales channels.
• Chen Baogui, General Manager of Taiwan, encouraged increasing inquiry volume to drive revenue growth through the Alibaba.com platform.

Reflections:
CHI FENG’s Sales Manager, Pei, shared her thoughts after the 90-minute discussion: “This exchange was incredibly valuable. Collaborating with a platform like Alibaba.com feels similar to our approach with customers—working closely with them in hospitals to understand market needs and improve products. It's a privilege to have this opportunity to align with Alibaba.com and explore the future of cross-border e-commerce in the medical industry.”